AstraZeneca PLC
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. […]
Read More
Is Novo Nordisk a get? Wall Avenue banking companies weigh in — and one offers it 36% draw back
For a lot of traders, the pounds loss drug boom has boosted Danish pharmaceutical big Novo Nordisk ‘s appeal this calendar year — but just one financial investment bank has reservations. “Above the coming yr, we envisage sentiment to change, most likely originally as a final result of the launch of competitor Eli Lilly ‘s […]
Read More
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More
'Large and very successful': Analysts like this biotech inventory and give it key upside
The biotechnology sector has last but not least picked up steam after a challenging 2022 — and one below-the-radar inventory stands out to fund manager Hugh Dive. That’s CSL Constrained , an Australian business that researches, develops and manufactures medicine and health care items. Medication in its portfolio include Aflunov, a vaccine for H5N1 influenza, […]
Read More
Weight gain after stopping Eli Lilly's new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by 0.12%, at $584.76 each — a […]
Read More
Eli Lilly vs. Novo Nordisk: The professionals supply their verdict on the viral body weight-reduction stocks
It has been really a calendar year for both Eli Lilly and Novo Nordisk given the increase in excess weight-reduction drugs. Stocks of both pharmaceutical corporations have rallied this 12 months. Shares in Eli Lilly are up all over 60% yr-to-date, while its Danish counterpart Novo Nordisk has noticed a achieve of about 50%. As […]
Read More
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced […]
Read More
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
A RSV-infected child receives treatment, as RS-Virus infections spread among children at Missio children’s clinic Moenchberg, in Wuerzburg, Germany, December 2, 2022. Heiko Becker | Reuters The Centers for Disease Control and Prevention expedited the release of more than 77,000 additional doses of a new drug designed to protect infants from respiratory syncytial virus amid […]
Read More
Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here’s why, analyst says
Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the answer is: “yes, but not to this degree.” Shin initiated coverage of a host of pharmaceutical stocks, including Eli Lilly, on Wednesday. The analyst said he is worried Lilly’s valuation is “grating against fundamentals,” as […]
Read More
European marketplaces advance as earnings enhance sentiment AstraZeneca up 2.7%
European markets edged higher on Thursday as momentum in marketplaces picked up on the back of robust corporate earnings. The pan-European Stoxx 600 was up .8% by mid-afternoon, obtaining reversed opening losses. Industrials included 2.1% to guide gains even though journey and leisure stocks dropped 2%. Earnings stay a critical driver of sentiment in European […]
Read More